Winner Medical Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jianquan Li

İcra Kurulu Başkanı

CN¥3.1m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	3.4yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3.4yrs

Son yönetim güncellemeleri

Recent updates

Winner Medical Co., Ltd. (SZSE:300888) Stock Rockets 25% But Many Are Still Ignoring The Company

Dec 12

Does Winner Medical (SZSE:300888) Have A Healthy Balance Sheet?

Nov 21

Winner Medical Co., Ltd.'s (SZSE:300888) Shares Lagging The Industry But So Is The Business

Sep 16

Estimating The Fair Value Of Winner Medical Co., Ltd. (SZSE:300888)

Aug 19

Investors Could Be Concerned With Winner Medical's (SZSE:300888) Returns On Capital

Aug 02

Is Winner Medical (SZSE:300888) Using Too Much Debt?

Jul 15

Winner Medical (SZSE:300888) Will Pay A Smaller Dividend Than Last Year

May 31

There May Be Reason For Hope In Winner Medical's (SZSE:300888) Disappointing Earnings

May 01

There Are Reasons To Feel Uneasy About Winner Medical's (SZSE:300888) Returns On Capital

Apr 26

CEO

Jianquan Li (67 yo)

3.4yrs

Görev süresi

CN¥3,073,400

Tazminat

Mr. Jianquan Li is Chief Executive Officer of Winner Medical Co., Ltd. and serves as its Non-Independent Director since July 13, 2021. He also serves as Chairman of Winner Medical Co., Ltd.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jianquan Li	CEO & Chairman	3.4yrs	CN¥3.07m	Veri yok
Xiuyuan Fang	Non-Independent Director	3.4yrs	CN¥1.64m	0.020% CN¥ 4.9m
Xiaodan Xu	Non-Independent Director	3.4yrs	CN¥1.06m	0.0039% CN¥ 972.4k
Ke Liu Key	Independent Director	3.4yrs	CN¥180.00k	Veri yok
Zhenwei Guo	Non-Independent Director	3.4yrs	Veri yok	Veri yok
Jianfeng Peng	Independent Director	3.4yrs	CN¥180.00k	Veri yok
Jiawei Xie	Independent Director	3.4yrs	CN¥180.00k	Veri yok
Tingting Zhang	Chairman of the Board of Supervisors	3.4yrs	Veri yok	Veri yok
Hua Liu	Employee Representative Supervisor	no data	Veri yok	0.0038% CN¥ 937.7k
Zhifang Wang	Independent Director	less than a year	Veri yok	Veri yok
Junfa Chen	Independent Director	less than a year	Veri yok	Veri yok
Xiangliang Yang	Independent Director	less than a year	Veri yok	Veri yok

3.4yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300888 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/21 07:15
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Winner Medical Co., Ltd. 11 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Fu Yang	Chasing Securities
Zhuonan Xu	China International Capital Corporation Limited
Junhao Fan	China International Capital Corporation Limited

Winner Medical Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

Winner Medical Co., Ltd., Annual General Meeting, May 21, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Winner Medical Co., Ltd., Annual General Meeting, May 13, 2022

Recent updates

Price target increased by 11% to CN¥39.33

Winner Medical Co., Ltd. (SZSE:300888) Stock Rockets 25% But Many Are Still Ignoring The Company

Now 23% undervalued

Does Winner Medical (SZSE:300888) Have A Healthy Balance Sheet?

Third quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥2.49 in 3Q 2023)

Now 21% overvalued after recent price rise

Investor sentiment deteriorates as stock falls 22%

Winner Medical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 13%

Winner Medical Co., Ltd. (SZSE:300888) acquired 75.2% stake in Global Resources International, Inc. for $120 million.

Winner Medical Co., Ltd. Announces Interim Cash Dividend of the Year 2024 of A Shares, Payable on 30 September 2024

Winner Medical Co., Ltd. Approves Interim Dividend for the Year 2024

Winner Medical Co., Ltd.'s (SZSE:300888) Shares Lagging The Industry But So Is The Business

Consensus EPS estimates fall by 14%

Second quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.52 in 2Q 2023)

High number of new directors

Estimating The Fair Value Of Winner Medical Co., Ltd. (SZSE:300888)

Investors Could Be Concerned With Winner Medical's (SZSE:300888) Returns On Capital

Is Winner Medical (SZSE:300888) Using Too Much Debt?

Winner Medical Co., Ltd. to Report First Half, 2024 Results on Aug 20, 2024

Winner Medical (SZSE:300888) Will Pay A Smaller Dividend Than Last Year

Dividend of CN¥0.50 announced

Winner Medical Co., Ltd. Announces Final Cash Dividend on A Shares for 2023, Payable on 04 June 2024

Price target decreased by 11% to CN¥37.77

Consensus EPS estimates fall by 20%

There May Be Reason For Hope In Winner Medical's (SZSE:300888) Disappointing Earnings

Winner Medical Co., Ltd. Proposes Final Cash Dividend for the Year 2023

There Are Reasons To Feel Uneasy About Winner Medical's (SZSE:300888) Returns On Capital

First quarter 2024 earnings released: EPS: CN¥0.31 (vs CN¥0.64 in 1Q 2023)

Winner Medical Co., Ltd., Annual General Meeting, May 21, 2024

Estimating The Fair Value Of Winner Medical Co., Ltd. (SZSE:300888)

Winner Medical Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Does Winner Medical (SZSE:300888) Have A Healthy Balance Sheet?

Now 21% overvalued

There's No Escaping Winner Medical Co., Ltd.'s (SZSE:300888) Muted Earnings

Investor sentiment improves as stock rises 24%

Now 26% overvalued

Winner Medical Co., Ltd. (SZSE:300888) announces an Equity Buyback for CNY 200 million worth of its shares.

Winner Medical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

Price target decreased by 9.2% to CN¥50.82

Third quarter 2023 earnings released: EPS: CN¥2.49 (vs CN¥0.61 in 3Q 2022)

New major risk - Revenue and earnings growth

Winner Medical Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Consensus EPS estimates increase by 34%, revenue downgraded

Second quarter 2023 earnings released: EPS: CN¥0.52 (vs CN¥0.92 in 2Q 2022)

Winner Medical Co., Ltd. to Report First Half, 2023 Results on Aug 16, 2023

Consensus EPS estimates increase by 38%, revenue downgraded

Winner Medical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 02 June 2023

Winner Medical Co., Ltd. Approves Cash Dividend for the Year 2022

Price target decreased by 9.3% to CN¥84.33

First quarter 2023 earnings released: EPS: CN¥0.89 (vs CN¥0.84 in 1Q 2022)

Now 20% undervalued after recent price drop

Now 20% undervalued

Price target increased to CN¥88.97

High number of new and inexperienced directors

Now 23% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: CN¥0.85 (vs CN¥0.81 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.28 (vs CN¥0.66 in 2Q 2021)

Price target increased to CN¥84.00

Winner Medical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on May 27, 2022

Winner Medical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on May 27, 2022

Winner Medical Co., Ltd. Announces Dividend for 2021

Price target decreased to CN¥84.58

Consensus revenue estimates fall by 11%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Winner Medical Co., Ltd., Annual General Meeting, May 13, 2022

Winner Medical Co., Ltd. Announces Final Dividend Proposal for 2021

Winner Medical Co., Ltd. (SZSE:300888) agreed to acquire 55% stake in Zhejiang Longtai Medical Technology Co., Ltd. from Wu Kangping, Huang Lepei and Wu Di for CNY 727.54 million.